Company intelligence / Profile preview

United Biomedical, Inc.

Ownership: Private
Development stage: Commercial

Overview

United Biomedical, Inc. (UBI) develops immunotherapeutics and vaccines for chronic and infectious diseases using proprietary synthetic peptide-based technologies and monoclonal antibodies. Its spinoffs have advanced candidates such as UB421 for HIV into multinational Phase II/III trials. The company has enabled the sale of billions of units based on its technologies in both human and animal health but does not market its own branded products directly.[1][2][3]

Therapeutic areas: OtherImmunologyNeurologyInfectious Diseases
Modalities: Synthetic peptidesMonoclonal antibodies (mAbs)Protein drugs
Industry: Biotech

Drug pipeline

4 assets

P3C541b

3 more assets in the full pipeline.

Request access →

Partnerships

Collaborates with global firms for commercializationpartnered with Taiwan government to form UBI Asia

Beyond the preview

Go deeper on United Biomedical, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on United Biomedical, Inc..

Explore the full profile